Brian Granda

2.9k total citations · 1 hit paper
26 papers, 1.9k citations indexed

About

Brian Granda is a scholar working on Pharmacology, Oncology and Infectious Diseases. According to data from OpenAlex, Brian Granda has authored 26 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Pharmacology, 10 papers in Oncology and 5 papers in Infectious Diseases. Recurrent topics in Brian Granda's work include Pharmacogenetics and Drug Metabolism (16 papers), HIV/AIDS drug development and treatment (5 papers) and CAR-T cell therapy research (4 papers). Brian Granda is often cited by papers focused on Pharmacogenetics and Drug Metabolism (16 papers), HIV/AIDS drug development and treatment (5 papers) and CAR-T cell therapy research (4 papers). Brian Granda collaborates with scholars based in United States, Switzerland and China. Brian Granda's co-authors include Lisa L. von Moltke, David J. Greenblatt, Richard I. Shader, Jerold S. Harmatz, Jeffrey M. Grassi, Karthik Venkatakrishnan, Su Duan, Johanna P. Daily, Steven M. Fogelman and Melissa Ramones and has published in prestigious journals such as Blood, Molecular Cell and Biochemistry.

In The Last Decade

Brian Granda

26 papers receiving 1.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice

2015 425 citations Xiaojun Liu, Shuguang Jiang et al. Cancer Research profile →

Peers

Countries citing papers authored by Brian Granda

Since Specialization

Citations

This map shows the geographic impact of Brian Granda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian Granda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian Granda more than expected).

Fields of papers citing papers by Brian Granda

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian Granda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian Granda. The network helps show where Brian Granda may publish in the future.

Co-authorship network of co-authors of Brian Granda

This figure shows the co-authorship network connecting the top 25 collaborators of Brian Granda. A scholar is included among the top collaborators of Brian Granda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian Granda. Brian Granda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clearance of plasma PCSK9 via the asialoglycoprotein receptor mediated by heterobifunctional ligands 2023 ·Cell chemical biology ·Jeffrey T. Bagdanoff, Thomas M. Smith, Martin Allan, Peter H. O’Donnell, (unknown), Elizabeth A. Moore, (unknown), Shuangxi Wang, Vanitha Subramanian, Bruno Tigani, David O. Nettleton, Lauren G. Monovich, Ian Lewis, (unknown), Brian Granda, John W. Blankenship, David Barnes‐Seeman, Kevin B. Clairmont	22
2	Identification and Development of PHE885: A Novel and Highly Potent Fully Human Anti-BCMA CAR-T Manufactured with a Novel T-Charge TM Platform for the Treatment of Multiple Myeloma 2021 ·Blood ·(unknown), (unknown), Nathaniel Barton, (unknown), (unknown), (unknown), (unknown), (unknown), Keith G. Mansfield, Brian Granda, Carla P. Guimarães, (unknown), Jennifer L. Brogdon	7
3	A CRISPR Screen Reveals Resistance Mechanisms to CD3-Bispecific Antibody Therapy 2020 ·Cancer Immunology Research ·Siqi Liu, (unknown), (unknown), Brian Granda, Rajiv Chopra, Srinivas Chakravarthy, (unknown), (unknown), (unknown), Katherine Seiss, William R. Tschantz, Tomáš Rejtar, David A. Ruddy, Tiancen Hu, Kimberly Aardalen, Joel P. Wagner, Glenn Dranoff, Joseph A. D’Alessio	14
4	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice breakdown → 2015 ·Cancer Research ·Xiaojun Liu, Shuguang Jiang, Chongyun Fang, (unknown), Devvora Olalere, Edward Pequignot, Alexandria P. Cogdill, Na Li, Melissa Ramones, Brian Granda, Li Zhou, Andreas Loew, Regina M. Young, Carl H. June, Yangbing Zhao	425
5	Methylation of p53 by Set7/9 Mediates p53 Acetylation and Activity In Vivo 2008 ·Molecular Cell ·Julia K. Kurash, Hong Lei, Qiong Shen, Wendy L. Marston, Brian Granda, Hong Fan, Daniel Wall, En Li, François Gaudet	178
6	INTERACTION OF TRIAZOLAM AND KETOCONAZOLE IN P-GLYCOPROTEIN-DEFICIENT MICE 2004 ·Drug Metabolism and Disposition ·Lisa L. von Moltke, Brian Granda, Jeffrey M. Grassi, Michael Perloff, Daesety Vishnuvardhan, David J. Greenblatt	30
7	Short‐Term Exposure to Low‐Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone 2003 ·The Journal of Clinical Pharmacology ·David J. Greenblatt, Lisa L. von Moltke, Jerold S. Harmatz, Steven M. Fogelman, Gengsheng Chen, Jennifer A. Graf, Polyxane Mertzanis, (unknown), (unknown), Brian Granda, Johanna P. Daily, Richard I. Shader	48
8	In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat 2002 ·Journal of Pharmacology and Experimental Therapeutics ·Tsutomu Kotegawa, Bart Laurijssens, Lisa L. von Moltke, Monette Cotreau, Michael Perloff, Karthik Venkatakrishnan, Jill S. Warrington, Brian Granda, Jerold S. Harmatz, David J. Greenblatt	88
9	Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors 2002 ·Drug Metabolism and Disposition ·(unknown), Lisa L. von Moltke, Karthik Venkatakrishnan, Brian Granda, Megan Gibbs, R. Scott Obach, Jerold S. Harmatz, David J. Greenblatt	61
10	Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine 2001 ·European Journal of Clinical Pharmacology ·(unknown), Karthik Venkatakrishnan, Brian Granda, Lisa L. von Moltke, David J. Greenblatt	85
11	Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors 2001 ·The Journal of Clinical Pharmacology ·Lisa L. von Moltke, David J. Greenblatt, Brian Granda, (unknown), Su Duan, Johanna P. Daily, Jerold S. Harmatz, Richard I. Shader	100
12	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors 2000 ·Biological Psychiatry ·(unknown), Lisa L. von Moltke, Brian Granda, J S Harmatz, Richard I. Shader, David J. Greenblatt	45
13	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects 1999 ·Biological Psychiatry ·Lisa L. von Moltke, David J. Greenblatt, Jeffrey M. Grassi, Brian Granda, Karthik Venkatakrishnan, Su Duan, Steven M. Fogelman, Jerold S. Harmatz, Richard I. Shader	75
14	Inhibition of human cytochrome P450 isoformsin vitro by zafirlukast 1999 ·Biopharmaceutics & Drug Disposition ·Richard I. Shader, Brian Granda, Lisa L. von Moltke, (unknown), David J. Greenblatt	23
15	Zolpidem metabolism in vitro: responsible cytochromes, chemical inhibitors, and in vivo correlations 1999 ·British Journal of Clinical Pharmacology ·Lisa L. von Moltke, David J. Greenblatt, Brian Granda, Su Duan, Jeffrey M. Grassi, Karthik Venkatakrishnan, J S Harmatz, Richard I. Shader	105
16	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions 1999 ·Psychopharmacology ·Lisa L. von Moltke, David J. Greenblatt, Brian Granda, Jeffrey M. Grassi, (unknown), Jerold S. Harmatz, Richard I. Shader	65
17	Multiple site interaction of triazolam and ketoconazole in mice: Role of P-glycoprotein 1999 ·Clinical Pharmacology & Therapeutics ·L VONMOLTKE, Brian Granda, Jeffrey M. Grassi, D J Greenblatt	4
18	Gepirone and 1-(2-pyrimidinyl)-piperazine in vitro: human cytochromes mediating transformation and cytochrome inhibitory effects 1998 ·Psychopharmacology ·Lisa L. von Moltke, David J. Greenblatt, Jeffrey M. Grassi, Brian Granda, Steven M. Fogelman, Jerold S. Harmatz, (unknown), Louis F. Fabre, Richard I. Shader	16
19	Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography 1998 ·Journal of Pharmacological and Toxicological Methods ·Brian Granda, (unknown), Lisa L. von Moltke, David J. Greenblatt	24
20	Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450 1998 ·Journal of Clinical Psychopharmacology ·Lisa L. von Moltke, David J. Greenblatt, Domenic A. Ciraulo, Jeffrey M. Grassi, Brian Granda, Su Duan, J S Harmatz, Richard I. Shader	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact